

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for all contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6855)**

### **VOLUNTARY ANNOUNCEMENT**

#### **Studies of HQP1351 nominated the “Best of ASH” at the 2019 American Society of Hematology Annual Meeting**

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) announced that an oral report (the “**Report**”) on clinical trial of innovative drug HQP1351 was presented and nominated the “Best of ASH” at the 2019 American Society of Hematology (“**ASH**”) Annual Meeting. The ASH Annual Meeting is the largest gathering of the international hematology field, bringing together the latest and most cutting-edge research and development in hematology.

HQP1351 is a novel third generation BCR-ABL tyrosine kinase inhibitor (“**TKI**”) for the treatment of patients with chronic myeloid leukemia (“**CML**”) resistant to first and second generation of TKIs. The results of preliminary Phase 1 study had been presented orally at the 2018 ASH Annual Meeting for the first time.

The Report is an update for the safety and preliminary efficacy of the Phase I study of HQP1351. It shows that HQP1351 was well tolerated and exhibited significant and durable antitumor activity in the patients with TKI-resistant CML, including those with T315I mutation.

As at the date of this announcement, the patient enrolment for the pivotal Phase II clinical trials of HQP1351 in China regarding CP-CML and AP-CML has completed. HQP1351 has started its Phase Ib clinical trial in the U.S.

### **About Ascentage Pharma**

Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The Company is dedicated to the discovery and development of innovative therapies with first- and best-in class potentials to address unmet medical needs globally. Leveraging its technical expertise in structure-based drug design and its innovative drug discovery engine, the Company has developed a robust pipeline of eight clinical stage small molecule drug candidates. The Company's pipeline consists of novel small molecule drug candidates that disrupt complex and difficult-to-target protein-protein interactions, or PPIs, and next generation tyrosine kinase inhibitors, or TKIs. As of June 30, 2019, the Company has 28 ongoing Phase I or II clinical trials in the United States, Australia and China.

For more information about Ascentage Pharma, please visit: [www.ascentagepharma.com](http://www.ascentagepharma.com).

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, December 11, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.*